Sensitization Potential of the Major Soybean Allergen Gly m 4 and Its Cross-Reactivity with the Birch Pollen Allergen Bet v 1.

Int J Mol Sci · 2025 · PMC11988912 · PMID 40243572

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

failed to reach statistical significanceno p-value reported

It has been also shown that double-blind placebo-controlled allergen immunotherapy by hypoallergenic Bet v 1 variant for patients with combined Bet v 1 and Gly m 4 sensitization failed to reach statistical significance in decreasing Gly m 4-specific IgE [ 11 ].

also in 6,035 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.